Medical - Diagnostics & Research · NYSE
当前价格
$464.37
内在价值
使用下方计算器估算
对 Thermo Fisher Scientific Inc. 运行完整的 DCF 分析，自动填充基本面数据，可调节假设参数，含敏感性热力图。
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
ROIC (TTM)
7.5%
ROE (TTM)
13.1%
FCF Yield
3.65%
基于过去 12 个月的数据，TMO 每股自由现金流为 N/A，投入资本回报率（ROIC）为 7.5%，这些是使用 DCF 方法进行股票估值的关键输入。P/FCF 比率为 N/A，FCF 收益率为 3.65%，是评估 TMO 相对估值的重要参考指标。
TMO 的内在价值取决于对未来增长率、折现率（WACC）和终值的假设。使用 MiniValuator 免费 DCF 计算器，输入你自己的假设进行估算，并查看敏感性分析热力图。
TMO 是否被低估取决于你的 DCF 假设。如果计算出的内在价值显著高于当前市价，则可能被低估。安全边际指示低估程度。在 MiniValuator 上运行完整估值来了解。
你可以使用 MiniValuator 的 DCF 计算器对 TMO 估值：输入代码，查看自动填充的基本面数据，调整增长率和折现率假设，即可获得含敏感性热力图的即时内在价值。
DCF（折现现金流）估值通过将公司未来预期自由现金流折现回现值来估算内在价值。对于 TMO，你输入预期增长率和折现率（WACC），模型会根据其未来现金产生能力计算股票当前应有的价值。
WACC（加权平均资本成本）是 TMO 估值中使用的折现率。较高的 WACC 会降低内在价值估算，较低的 WACC 则会提高。使用 MiniValuator 的敏感性热力图查看不同 WACC 假设对 TMO DCF 估值结果的影响。
